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Elevated plus-mazeGlutamatergic dysfunction is strongly implicated in schizophrenia and mood disorders. GluA1 knockout (KO)
mice display schizophrenia- and depression-related abnormalities. Here, we asked whether GluA1 KO show
mania-related abnormalities. KOwere tested for behavior in approach/avoid conﬂict tests, responses to repeated
forced swimexposure, and locomotor responses under stress and after psychostimulant treatment. The effects of
rapid dopamine depletion and treatment with lithium or a GSK-3β inhibitor (SB216763) on KO locomotor
hyperactivity were tested. Results showed that KO exhibited novelty- and stress-induced locomotor
hyperactivity, reduced forced swim immobility and alterations in approach/avoid conﬂict tests. Psychostimulant
treatment and dopamine depletion exacerbated KO locomotor hyperactivity. Lithium, but not SB216763,
treatment normalized KO anxiety-related behavior and partially reversed hyperlocomotor behavior, and also
reversed elevated prefrontal cortex levels of phospho-MARCKS and phospho-neuromodulin. Collectively, these
ﬁndings demonstrate mania-related abnormalities in GluA1 KO and, combined with previous ﬁndings, suggest
this mutant may provide a novel model of features of schizoaffective disorder.e and Genetics, Laboratory for
l Abuse and Alcoholism, 5625
A. Fax: +1 301 480 1952.
irect.com).
license. © 2010 Elsevier Inc.Open access under CC BY license. Introduction
Genes and molecules involved in excitatory synapse function are
attractive candidates as risk factors for psychiatric conditions with a
broad clinical phenotype such as schizoaffective disorder. Such
‘synaptologies’ have been posited to underlie neurodevelopmental
disorders such as autism (Sudhof, 2008; Feyder et al., in press) but
could also contribute to the pathophysiology of neuropsychiatric
disorders with a major developmental component such as schizoaffec-
tive disorder. In this context, L-glutamate is the major excitatory
neurotransmitter system in the central nervous system and a key
regulator of synaptic function and plasticity (Malenka and Bear, 2004).
Glutamatergic dysfunction is strongly implicated in schizophrenia and
mood disorders (Coyle, 2006).Glutamatergic neurotransmission is mediated by an array of
receptors belonging to the ionotropic (α-amino-3-hydroxy-5-methyl-
4isoxazole propionate [AMPAR], N-methyl-D-aspartate [NMDAR], kai-
nate) and metabotropic receptor (mGluR) subfamilies. AMPAR are
postsynaptic heteromeric proteins composed of one or more glutamate
receptor GluA1–GluA4 subunits (Shi et al., 2001). The GluA1/2
heteromer, and coupling to its downstream intracellular signaling
pathways, is altered in rodents by treatmentwith anti-manic drugs (e.g.,
lithium, valproate) and mania-inducing manipulations (e.g., psychos-
timulant treatment) (Du et al., 2007, 2008). There are also reports of
reduced GluA1 gene expression in the post-mortem brains of persons
with bipolar disorder (Beneyto et al., 2007).
Important insight into the potential role of the GluA1 subtype has
come from studies in mutant mice with targeted deletion of GluA1
(GluA1 ‘knockout,’ KO). For example, we recently reported that GluA1
KO caused multiple behavioral abnormalities considered relevant to
schizophrenia (Wiedholz et al., 2008). Interestingly, we and others have
also found that GluA1 KO exhibit disturbances on tests for emotionality
(Bannerman et al., 2004; Feyder et al., 2007; Mead et al., 2006;
Vekovischeva et al., 2004), and develop a ‘depression-related’
Table 1
GluA1 are normal on simple measures of physical health, and neurological and sensory
functions. Physical health, sensory reﬂexes, motor, neurological functions and simple
behaviors in an empty cage were generally no different between genotypes. A greater
proportion of KO exhibited missing whiskers and bald patches, forepaw clutching and
defecation in an empty cage than WT. Unless a unit of measurement is given in
parenthesis, data are the percentage of mice within each genotype showing a response
(n=14/genotype).
Redrawn from (Wiedholz et al., 2008).
WT KO
Physical health
Missing whiskers 20 47
Bald patches 13 27
Piloerection 0 0
Exophthalmus 0 0
Palpebral closure 0 0
Straub tail 0 0
Kinked tail 0 0
Kyphosis 0 0
Lordosis 0 0
Body weight (g) 21.5 22.9
Core body temp (°C) 36.5 36.3
Sensory reﬂexes
Approach response 100 100
Touch response 100 100
Palpebral response 100 80
Tail pink response 100 100
Hotplate paw withdrawal latency (sec) 11.49±0.86 9.67±0.94
Tail ﬂick latency (sec) 2.02±0.07 1.85±0.15
Motor, neurological
Splayed limbs 0 0
Forepaw clutch 0 13
Hindpaw clutch 0 0
Empty cage behaviors










Head bobbing 0 0
Circling 0 0
Abnormal gait 0 0
Retropulsion 0 7
Prancing forelimbs 0 0
609P.J. Fitzgerald et al. / Neurobiology of Disease 40 (2010) 608–621phenotype on various tests that entail repeated exposure to stressful
situations (Chourbaji et al., 2008). The pleiotropic nature of genetic
deletion of GluA1 suggests that the phenotype of these mutants may
more closelymodel features ofmore thanoneneuropsychiatric disorder
rather than any one major affective or psychotic condition alone.
There is an increasing view that despite their diagnostic demarca-
tion, certain forms of severe psychotic and mood disorders have a
commonpathophysiological basis (Owen et al., 2007). This is supported
by the observation that the prevalence of schizophrenia and bipolar
disorder tends to cluster in families and share a genetic component
(Cardno et al., 2002; Kendler et al., 1998; Owen et al., 2007; Park et al.,
2004; Potash et al., 2003). It has also recently been shown that bipolar
disorder and major depressive disorder share a genetic susceptibility
locus (McMahon et al., 2010). Clinically, individuals who exhibit ‘illness
during which there is a major depressive, manic, or mixed episode
concurrent with symptoms that meet criterion [A] for schizophrenia’
meet diagnostic criteria for schizoaffective disorder (DSM-IV, 1994).
However, the speciﬁc genetic and molecular factors that put an
individual at risk for schizoaffective disorder, rather than a more
discrete psychotic or depressive disorder, are not well understood.
Given previous studies have found that GluA1 KO mice exhibit
schizophrenia- and depression-related abnormalities, the aim of the
present study was to evaluate these mutants for other features of
schizoaffective disorder with a focus on themanic component. Mania is
characterized by hyperactivity of movement and thought, and can be
precipitatedor exacerbatedby stress (Ambelas, 1979;Malkoff-Schwartz
et al., 2000). We assayed GluA1 KO mice for locomotor responses to
novelty and stress in an open ﬁeld and behavioral responses to novel
and repeated forced swim. Because the manic component is also
associated with increased self-esteem, risk-taking and novelty-seeking,
we tested the mutants for anxiety-related and novelty-seeking
behaviors in various tasks that differentially test these two drives
(elevated plus- and zero-maze, light/dark emergence test, stress-
induced hyperthermia).
We went on to explore potential neurobiological mechanisms
underlying behavioral abnormalities in GluA1 KO. We tested whether
the KO phenotype was rescued by two drugs with known or hypothe-
sized efﬁcacy in bipolar disorder or schizophrenia, lithium and the
glycogen synthase kinase-3 beta inhibitor, SB216763. Moreover, given
our earlier ﬁnding that these KO mice had impaired striatal dopamine
clearance (Wiedholz et al., 2008), we tested whether the hyperloco-
motor phenotype was rescued by depletion of brain dopamine. To
identify molecular mechanisms associated with the GluA1 KO pheno-
type and its predicted rescue by lithium, we evaluated the activity of
two markers (MARCKS and neuromodulin) of protein kinase C (PKC),
an intracellular pathway implicated in mania (Szabo et al., 2009).
Materials and methods
Subjects
GluA1 KO were generated as previously described (Zamanillo
et al., 1999) on a 129S1/Sv-p+Tyr+KitlSl−J/+×129X1/SvJ back-
ground. We have previously found these mice to be normal on a range
of simple measures of physical health, neurological and sensory
functions (Wiedholz et al., 2008) (Table 1; male WT=8, female
WT=6,male KO=8, female KO=6; counts by experimental group (n)
in legend), and motor coordination (Palachick et al., 2008). For the
overall study, experiments were performed at the NIAAA unless
otherwise stated. In order to reduce the number of mice used, but at
the same timeminimize potential carry-over effects due to, e.g., stress of
test exposure, some mice were tested on multiple assays (details given
below), with putatively more stressful tests later in a sequence and at
least 1 week between tests (unless otherwise stated). Mice were 2–
10 months old at the time of the experiments. On the basis of our
previous ﬁnding that schizophrenia-related phenotypes (Wiedholz etal., 2008), as well fear-related and alcohol-related phenotypes (Feyder
et al., 2007; Palachick et al., 2008), inGluA1KOdid not vary as a function
of sex, the current study used both males and females in order to
increase the power of the analyses, without balancing sex ratio or
considering sex as a factor in the analyses. Another one of our studies
found similar behavioral results between male and female GluA1 mice
across a number of measures (Bannerman et al., 2004).
NIAAA experiments
Mice were backcrossed to produce a N75% C57BL/6J background, as
veriﬁed by genome scan (Wiedholz et al., 2008). WT and KO were
littermates bred from heterozygous×heterozygous parents (to reduce
potential inﬂuence of maternal genotype; Millstein et al., 2006), either
bred at The Jackson Laboratory and transported to NIH at ~8 weeks of
age, or bred in-house. Non-mutant C57BL/6J mice used in the GYKI
52466 experiments were males obtained from The Jackson Laboratory
and transported to NIH at ~8 weeks of age. Mice were housed in same-
sex groupings in a temperature- and humidity-controlled vivarium
under a 12 h light/dark cycle (lights on 0600 h) and tested in the light
phase. Experimental procedures were performed in accordance with
the National Institutes of Health Guide for Care and Use of Laboratory
610 P.J. Fitzgerald et al. / Neurobiology of Disease 40 (2010) 608–621Animals and were approved by the local Animal Care and Use
Committee. The number of mice used in all experiments is given in
the ﬁgure legends.
Oxford experiments
Mice were maintained on a C57BL/6J×CBA/J background. WT and
KOwere littermates bred in-house from heterozygous×heterozygous
parents. Mice were housed in same-sex groupings in a temperature-
and humidity-controlled vivarium under a 12 h light/dark cycle
(lights on 0700 h) and tested in the light phase. Experimental
procedures were approved by the Home Ofﬁce.
Mannheim experiments
Mice were backcrossed to C57BL/6J for N10 generations. WT and
KO were littermates bred in-house from heterozygous parents. Mice
were housed in a temperature- and humidity-controlled vivarium
under a 12 h reversed light/dark cycle (lights off 0600 h) and tested in
the dark phase. Experimental procedures were approved by the
German animal welfare authorities (Regierungspräsidium Karlsruhe).
Locomotor response to novelty and acute stress
As manic and psychotic episodes can be triggered by stress, we ﬁrst
tested separate cohorts of mice for locomotor responses to 3 different
relatively mild stressors [1: a novel open ﬁeld, 2: acute injection stress
(which is sufﬁcient to activate the hypothalamic-pituitary-adrenal axis
inmice; Li et al., 2004), and3: acute restraint stress], aswell as activity in
a non-stressful home-cage-like environment (Oxford).
Novel open ﬁeld
The open ﬁeld apparatus was a square arena (39×39×35 cm) with
opaque white Plexiglas walls and ﬂoor. It was evenly-illuminated to
~60 lx. Mice (male WT=8, female WT=7, male KO=8, female
KO=7) were placed in a corner and allowed to freely explore for
10 min. Total distance traveled and time spent in the (20×20 cm)
center was measured using the Ethovision videotracking system
(Noldus Information Technology, Leesburg, VA). The effect of genotype
was analyzed using Student's t-test.
Injection stress
Following a 30-min period of acclimation to the open ﬁeld (as
above), mice (male WT=3, female WT=5, male KO=6, female
KO=1) were given an intraperitoneal (i.p.) injection of 0.9% saline
(volume of 10 ml/kg bodyweight) and returned to the open ﬁeld. Total
distance traveled was recorded for a further 30 min. For all i.p.
injections, mice were held in a level, supine position by the
experimenter, and injected in the abdomen. Injections were made
midwaybetween thehip andmidline,with the injectionneedle inserted
at ~30° angle.
Brief restraint stress
Following a 30-min period of acclimation to the open ﬁeld (as
above), mice (male WT=7, female WT=3, male KO=4, female
KO=5)were removed and restrained in a 50 ml Falcon tube (Mozhui et
al., 2010) for 5 min before being returned to the open ﬁeld for 30 min.
For both stress experiments, the effects of genotype and time on
baseline pre-stress and post-stress locomotor activity were analyzed
using 2-factor analysis of variance (ANOVA), with repeated measures
for time, followed by Bonferroni–Dunn post hoc tests. Stress-induced
changes in locomotor activity were analyzed by comparing the minute
post-stress with the minute pre-stress (i.e., minute 31 vs. 30).
Home-cage-like assay (Oxford)
Mice (same as previously tested in the elevated plus-maze; male
WT=24, female WT=21, male KO=21, female KO=26) were singly
placed in a cage (22.5×12.5×13 cm)with clean bedding and ad libitumfood and water for 9.5 hr (0930–1900 h). Beginning at the onset of the
dark phase (1900 h) activity was measured primarily using the Med
Associates Threshold system (Med Associates Inc., St. Albans, VT).
Threshold pressure pads convert changes in pressure on pads into
changes in voltage. The threshold range was set to 20–50 V, the time
spent between these valuesbeing takenas time spentmoving. The effect
of genotype was analyzed using Student's t-test.
Response to novel and repeated forced swim stress
We next tested for behavioral responses to the more intense stress
of forced swimming. We examined responses to both acute and
repeated (2 trials and 5 trials) forced swim test (FST) stress in
separate cohorts of mice (apparatus and procedure as described,
Hefner and Holmes, 2007). To measure the HPA-axis response to
acute swim stress, we assayed blood corticosterone levels 30 min after
a single FST (procedure as described, Boyce-Rustay et al., 2007). To
analyze behavioral responses to repeated swim stress in greater
detail, we conducted a separate experiment (Oxford) using amodiﬁed
version of the forced swim test that distinguishes immobility,
swimming and climbing behavior (Cryan et al., 2005).
2-trial forced swim
We ﬁrst conducted a 2-trial procedure mimicking the original
procedure of Porsolt (Porsolt et al., 1977) in which a 15-min trial 1 is
followed by a shorter, 6-min, trial 2 24 h later. For each trial, mice (male
WT=8, female WT=7, male KO=8, female KO=7) were gently
placed in a 20 cm-diameter cylinder ﬁlled to ~13 cm with 24±1.0 °C
water (Hefner et al., 2007) and scored for immobility (cessation of limb
movements except minor movement necessary to keep the mouse
aﬂoat) every 5 s and expressed as the percent number of instances of
immobility during min 3–6 of each trial. This design provides 1) a
measure of immobility duringmin 3–6 of an initial exposure, equivalent
to the standard forced swim test procedure used for mice (Cryan and
Holmes, 2005), and 2) a measure of the change in immobility produced
by a prior lengthy swimexposure. The effects of genotype and trialwere
analyzed using 2-factor ANOVA, with repeated measures for trial,
followed by Bonferroni–Dunn post hoc tests.
5-trial forced swim
Here, we examined the development of immobility over an
extensive history of ﬁxed-length, repeated swims (in a naïve cohort).
Mice (previously tested in the elevated plus-maze and home-cage
activity tests; male WT=7, female WT=11, male KO=10, female
KO=3) were given a 10-min trial each day for 5 consecutive days.
Immobility was scored during min 3–10 of each trial. The effects of
genotype and trial were analyzed using 2-factor ANOVA, with repeated
measures for trial, followed by Bonferroni–Dunn post hoc tests.
Corticosterone response to swim
A separate cohort of swim-naïve mice (male WT=3, female
WT=6,male KO=6, female KO=6)were exposed to a single 10-min
swim stress (as above) and returned to the home cage. Thirty minutes
later, mice were sacriﬁced (between 1000–1200 h) via rapid cervical
dislocation and decapitation to collect trunk blood. Non-stressed
controls were sacriﬁced at the same time. Blood samples were
centrifuged at 13,000 rpm for 30 s. Serum was extracted and assayed
for total corticosterone (bound and free) using the Coat-a-Count RIA
TKRC1 kit (limit of detection: 5.7 ng/ml; Diagnostic Products Corp,
Los Angeles) as previously described (Boyce-Rustay et al., 2007). The
effects of genotype and stress were analyzed using 2-factor ANOVA.
Modiﬁed forced swim test (Oxford)
The apparatus and procedure were the same as for the 2-trial test
abovewith the exception that the cylinderwasﬁlled to 15 cmwithwater
and, in addition to immobility, swimmingandclimbing (movementwhile
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analyzed during an identical window on both days betweenminutes 3–6
(male WT=12, female WT=10, male KO=12, female KO=14). The
effects of genotype and trial were analyzed using 2-factor ANOVA, with
repeated measures for trial, followed by Bonferroni–Dunn post hoc tests.
Approach/avoidance behaviors in tests for anxiety-like behavior
We assessed GluA1 mutants in the elevated plus-maze — a test for
anxiety-like behavior based upon a conﬂict between avoidance and
approach (Cryan and Holmes, 2005). Because abnormal mouse
phenotypes in the elevated plus-maze appear prone to variation across
laboratories (Crabbe et al., 1999), we conducted parallel elevated plus-
maze experiments in the NIAAA and Oxford laboratories. In addition,
given evidence that differentmouse approach/avoidance tasksmeasure
partly distinct forms of behavior (Brigman et al., 2009), we assessed the
GluA1mutants in 2 other approach/avoidance tasks: the elevated zero-
maze (Mannheim) and light/dark emergence test (NIAAA). Finally, to
further parse anxiety- and novelty-seeking-related phenotypes, we
tested for 1) stress-induced hyperthermia, an anxiety assay (Groenink
et al., 1994), and2) responses to repeated exposure to the elevatedplus-
maze (Holmes et al., 2000).
Elevated plus-maze (NIAAA)
The apparatus consisted of 2 open arms (30×5 cm; 90 lx) and 2
closed arms (30×5×15 cm; 20 lx) extending from a 5×5 cm central
area and elevated 47 cm from the ground (San Diego Instruments, San
Diego, CA). The walls were made from black ABS plastic and the ﬂoor
fromwhite ABS plastic. A 0.5 cm raised lip around the perimeter of the
open arms preventedmice from falling off the maze. Mice (previously
tested in the novel open ﬁeld; male WT=7, female WT=7, male
KO=8, female KO=7) were placed in the center facing an open arm
and allowed to explore the apparatus for 5 min. Time spent in the
open arms, center square and closed arms, and entries into the open
arms, center square and closed arms was measured by the Ethovision
videotracking system (Noldus Information Technology Inc., Leesburg,
VA), with the center of mass of the mouse determining its arm
location. The effect of genotype was analyzed using Student's t-test.
Elevated plus-maze (Oxford)
The apparatus and procedure were the same as the NIAAA version
with the following exceptions: 1) the dimensions and lighting
conditions were 35×6 cm (open arms, 85 lx), 35×6×20 cm (closed
arms, 10 lx) and 6×6 cm (center square) and elevated 70 cm from the
ground, and 2) the maze was made of dark gray plastic. Behavior was
measured by the Ethovision videotracking system, with 3 body points
(front, center and back of the body) determining its arm location. The
effect of genotype was analyzed using Student's t-test (same mice as
tested in the home-cage-like assay).
Elevated zero-maze (Mannheim)
The apparatus consisted of an annular runway (width 6 cm, outer
diameter 46 cm, 50 cm above ground level) comprising 2 enclosed
quadrants (10 cm high inner and outer walls) separating 2 open
quadrants (25 lx). The walls and ﬂoor were made from gray plastic.
Mice (all male) were placed in a closed quadrant and allowed to
explore the apparatus for 5 min, and behavior was measured by the
Ethovision videotracking system,with the center ofmass of themouse
determining its arm location. The effect of genotype was analyzed
using Student's t-test.
Light/dark emergence test
The apparatus comprised a square opaque black Plexiglas ‘shelter’
(16×16×19 cm) with a single exit (6×4 cm) facing out into an open
ﬁeld arena (39×39×35 cm) with opaque white Plexiglas walls and
ﬂoor that was evenly-illuminated to ~90 lx. Mice (previously tested inthe novel open ﬁeld, and elevated plus-maze; male WT=8, female
WT=7, male KO=8, female KO=7) were placed in the shelter and
allowed to freely explore the whole apparatus for 5 min. Time out of
the shelter, number of shelter exits, and time and frequency of scans
of the open ﬁeld from the shelter (head and b4 paws out of the
shelter) were manually measured using the Hindsight behavioral
observation system (Scientiﬁc Programming Services, Wokingham,
UK). The effect of genotype was analyzed using Student's t-test.
Stress-induced hyperthermia
Mice (previously assayed on the functional observation battery;
male WT=3, female WT=3, male KO=7, female KO=0) were
individually housed in a clean, empty cage for 5 h to avoid disturbance
resulting from handling of cage mates (Van der Heyden et al., 1997).
Core body temperature was measured using a peanut oil-lubricated
physiological thermometer probe (Thermalert TH-5, Physitemp,
Clifton, NJ) inserted 2 cm into the rectum for ~10 s on 2 occasions
separated by 10 min. Stress-induced hyperthermia is the increase in
core body temperature between the 2 measurements. The effect of
genotype was analyzed using Student's t-test.
Repeated exposure to elevated plus-maze
Test-naïve mice (male WT=13, female WT=9, male KO=9,
female KO=9) were tested as above (NIAAA version) over 2 trials,
separated by 24 h. The effects of genotype and trial were analyzed
using 2-factor ANOVA, with repeated measures for trial, followed by
Bonferroni–Dunn post hoc tests.
Effects of AMPAR/kainate antagonist GYKI 52466
Behavioral abnormalities in GluA1 KO could arise from either loss
of GluA1 function in the adult brain or indirect abnormalities arising
from alterations in neural development. One indirect way to address
this issue is to ask whether pharmacological inactivation of GluA1 in
adult non-mutant mice phenocopies the effects of constitutive GluA1
KO. There are currently no GluA1-selective antagonists, precluding a
direct comparison. However, the antagonist GYKI 52466 has relative
selectivity for AMPA and kainate receptors over other glutamate
receptors and has behavioral effects in rats and NSAmice (Tzschentke
and Schmidt, 1997; Vanover, 1998). We tested the effects of systemic
GYKI 52466 in non-mutant C57BL/6J mice (genetic background of
GluA1 KO; all male) on novel open ﬁeld and elevated plus-maze
assays (in the samemice) under the same conditions which produce a
robust phenotype in GluA1 KO.
The novel open ﬁeld and elevated plus-maze tests used to test
C57BL/6J mice involved the same apparatuses and procedures as
described above (NIAAA version). For each experiment, mice were
tested 30 min after treatment with 0, 0.5, 2.5, 5, or 10 mg/kg GYKI
52466 (Sigma, St. Louis, MO, dissolved in a vehicle of 10% Dimethyl
sulfoxide (DMSO) and 90% 0.9% saline) injected i.p. in a volume of
10 ml/kg body weight. This vehicle did not produce any observable
behavioral effects. Doses were chosen on the basis of previous
behavioral studies in mice (Kapus et al., 2008; Vekovischeva et al.,
2007). The effect of dose was analyzed using ANOVA.
GluA1 KO have redistribution of GluA2/3 (Zamanillo et al., 1999),
and it remains possible that there is a compensatory functional
upregulation of AMPAR. Therefore, we tested whether the effects of
GYKI 52466 in the novel open ﬁeld were altered in KO, as a probe for
effects on GluA2/3 in themutants (maleWT=3, femaleWT=8, male
KO=6, female KO=0). Test-naïve mice were injected i.p. with 0 or
10 mg/kg GYKI 52466 and immediately tested in a novel open ﬁeld
for 30 min. A within-subjects Latin square design was employed, in
which half the mice received vehicle one day and drug the next day,
and vice versa for the other half. The effect of genotype and treatment
was analyzed using ANOVA, with repeated measures for treatment.
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Prior studies have consistently demonstrated novelty-induced
locomotorhyperactivity inGluA1KO(Bannermanet al., 2004;Chourbaji
et al., 2008; Vekovischeva et al., 2004; Wiedholz et al., 2008). This
phenotype is potentially relevant to a number of neuropsychiatric
conditions (e.g., schizophrenia, bipolar disorder, ADHD), but does not
discriminate between them. By contrast, psychostimulants such as
amphetamine (Adderall) and methylphenidate (Ritalin) would be
predicted to exacerbate a bipolar- or schizophrenia-related phenotype
(Anand et al., 2000; Einat and Manji, 2006), but normalize an ADHD-
related phenotype given their therapeutic efﬁcacy for ADHD. We
therefore tested test-naïve separate cohorts of GluA1 KO for locomotor
responses to hyperlocomotor-inducing (sub-stereotypic) doses of
amphetamine and methylphenidate.
We tested the hyperlocomotor-inducing effects of amphetamine
using a within-subjects experimental design previously used to test
for mania-related phenotypes in GluA6 KOmice (Shaltiel et al., 2008).
Mice (male and female counts not determined) were given a 60 min
period of habituation to the open ﬁeld and then injectedwith 2 mg/kg
amphetamine (Sigma, St. Louis, MO, dissolved in 0.9% saline and
injected i.p. in a volume of 10 ml/kg body weight) and returned to the
open ﬁeld for 10 min. The effect of genotype and (10-min) pre- vs.
(10-min) post-drug period was analyzed using ANOVA, with repeated
measures for period, followed by Bonferroni–Dunn post hoc tests and
Bonferroni-corrected t-tests. In addition, the effect of genotype on the
drug-induced increase in total distance traveled (=post-drug minus
pre-drug) was analyzed using Student's t-test.
We tested the hyperlocomotor-inducing effects of methylpheni-
date in a separate cohort, using a between-subjects design. Mice
(male WT=8, female WT=10, male KO=12, female KO=6) were
given a 60 min period of habituation to the open ﬁeld and then
injected with vehicle or 5 mg/kg methylphenidate (Sigma, St. Louis,
MO, dissolved in 0.9% saline and injected i.p. in a volume of 10 ml/kg
body weight) and returned to the open ﬁeld for 10 min. Methylphe-
nidate-induced locomotor activity was measured as the difference in
drug relative to vehicle locomotor activity. The effect of genotype and
drugwas analyzed using ANOVA. In addition, the effect of genotype on
the drug-induced increase in total distance traveled (=drug minus
vehicle) was analyzed using Student's t-test.
Effects of rapid dopamine depletion
Impaired dopaminergic function is implicated in schizophrenia and
bipolar disorder. We previously found that GluA1 KO have impaired
dopamine clearance in the striatum, and that the KO hyperlocomotor
phenotype was rescued by treatment with the dopamine D2 receptor
antagonist haloperidol (Wiedholz et al., 2008). These data suggest that
excessive striatal dopaminemayunderlie theGluA1KOhyperlocomotor
phenotype. To test this hypothesis, we examined the effects of rapid
depletion of dopamine (via treatment with the tyrosine hydroxylase
inhibitor α-methyl-p-tyrosine methyl ester (AMPT)) on locomotor
activity (Costa et al., 2006; Gainetdinov et al., 1999). To verify depletion,
striatal dopamine (and serotonin) tissue content, as well asmetabolites
of these two neurotransmitters, was measured immediately after
testing.
Mice (previously tested in stress-induced hyperthermia assay;
male WT=16, female WT=15, male KO=14, female KO=10) were
injected i.p. (volume of 10 ml/kg body weight) with 0 or 200 mg/kg
AMPT (Sigma, St. Louis, MO, dissolved in 0.9% saline) and, 60 min
later, tested in a novel open ﬁeld (apparatus and procedure as
described above) for 30 min. Dose was selected based on pilot work
and previous studies (Costa et al., 2006; Gainetdinov et al., 1999) to
cause signiﬁcant dopamine depletion but not signiﬁcant locomotor
hypoactivity in WT. The effect of genotype and treatment was
analyzed using ANOVA, followed by Bonferroni–Dunn post hoc tests.Immediately after openﬁeld testing, a subset ofmice (maleWT=11,
female WT=10, male KO=14, female KO=6) were sacriﬁced via
cervical dislocation anddecapitation to verify reduced striatal dopamine
content via high performance liquid chromatography (HPLC), as
previously described (Boyce-Rustay et al., 2008). A dissection of the
striatum (also containing septum) was made on ice and tissue was
frozen at −80 °C. Frozen samples were homogenized by ultrasonic
processing in 800 μl of 0.1 M perchloric acid containing 1% ethanol and
0.02% EDTA and centrifuged for 20 min at 3000 g. Thirty microliters of
the homogenate was used for analysis using a Luna 5μC18(2),
250×2.0 mm column (Phenomenex 00G-4252-B0, Torrance, CA)
held at 30 °C, Waters Corporation (Milford, MA) 717plus autosampler
at 4 °C, 510 pump at 0.4 ml/min and amperometric electrochemical
detector (EiCOM CB100) set at Eox. 0.82 V. The mobile phase contained
2.8 g 1-heptanesulfonic acid sodium salt, 0.17 g EDTA, 20 ml triethyla-
mine, dissolved in 2.2 l water, pH adjusted to 2.5 with 13 ml 85%
phosphoric acid, plus 90 ml acetonitrile. Adjusted to 1 l total volume,
these values are: 1.21 g 1-heptanesulfonic acid sodium salt, 0.073 g
EDTA, 8.61 ml triethylamine, dissolved in 947.1 ml water, pH adjusted
to 2.5 with 5.60 ml 85% phosphoric acid, plus 38.74 ml acetonitrile. The
detector output was recorded and analyzed with Waters Empower 2
Chromatography Data Software. No internal standard was used for this
assay. Thequantiﬁcationwasagainst external standards injected several
times during the run (before the samples, every 12 samples, and post-
sample injections). We examined tissue content levels of dopamine
and its monoamine metabolites 3,4-dihydroxyphenylacetic acid
(DOPAC), homovanillic acid (HVA), and its catechol-O-methyltransfer-
ase metabolite 3-methoxytyramine (3-MT), as well as norepinephrine
(NE), and 5-hydroxytryptamine (5-HT) and its monoamine metabolite
5-hydroxyindole-3-acetic acid (5-HIAA). The effect of genotype and
treatment was analyzed using ANOVA, followed by Bonferroni–Dunn
post hoc tests.
Effects of GSK-3β inhibitor
There is growing evidence supporting the contribution of glycogen
synthase kinase-3 beta (GSK-3β) to the pathophysiology and
treatment of schizophrenia and bipolar disorder (Gould and Manji,
2002). We therefore asked whether GSK-3β inhibition would
normalize the locomotor hyperactivity and forced swim abnormali-
ties in GluA1 KO by treatingmice with 2 mg/kg SB216763 every other
day for 11 days (i.e., 6 treatments in total, similar to Mao et al., 2009)
and subsequently testing in the open ﬁeld and repeated FST assays. To
mimic the procedure used by Mao et al., we tested mice in both the
open ﬁeld and repeated FST assays.
Test-naïve mice (male WT=12, female WT=14, male KO=11,
female KO=15) were treated with 2 mg/kg SB216763 (Sigma, St.
Louis,MO, dissolved in 90% 0.9% saline/10%DMSO and injected i.p. in a
volume of 10 ml/kg body weight) every other day for 10 days (i.e., as
previously described (Mao et al., 2009)). On day 10, mice were tested
in the open ﬁeld for 10 min (apparatus and procedure as described
above). Mice received another drug treatment on day 11, and on days
12 and 13 were given a 15 min and then 6-min forced swim exposure,
respectively (apparatus and procedure as described above). The effect
of genotype and treatment was analyzed using ANOVA.
Effects of lithium treatment
A key test of whether GluA1 KObehavioral abnormalities aremania-
related is whether they are rescued by treatment with an anti-manic
drug such as lithium (O'Donnell and Gould, 2007). We chronically
treated test-naïve mice with lithium for 14 days (Gould et al., 2007;
Shaltiel et al., 2008) and then over subsequent days (while still on-drug)
tested in the novel open ﬁeld (male WT=13, female WT=18, male
KO=9, female KO=20) and elevated plus-maze (maleWT=6, female
WT=12, male KO=6, female KO=10). Because the PKC pathway has
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et al., 2009), we probed this pathway at baseline and after lithium
treatment by quantifying phosphorylation of the PKC activity markers
myristoylated alanine-rich C kinase (MARCKS; male WT=5, female
WT=6, male KO=6, female KO=6) and neuromodulin (growth
associated protein 43, GAP43; male WT=5, female WT=7, male
KO=6, female KO=6). (Note, to avoid potentially confounding effects
of stress on thesemolecularmeasures, we did not test for lithium effects
on forced swim test behavior in this experiment.)
Regular rodent chow was loaded with 4 g/kg lithium carbonate
(Bio-Serv, Frenchtown, NJ, USA) to produce brain lithium levels of
~0.55 mM and plasma levels in the human therapeutic range
(~1.0 mM) (Shaltiel et al., 2008). Non-treated controls received the
same chow with no lithium. Because lithium produces polyuria and
polydipsia, all mice (including controls) had their chow moistened
daily in 0.9% saline, and cage bedding was changed approximately
three times weekly. On day 15, mice were tested in the open ﬁeld for
10 min (apparatus and procedure as described above), and the data
analyzed in 2-min timebins to investigate within-session effects of
lithium. On day 16, mice were tested in the elevated plus-maze
(NIAAA; apparatus and procedure as described above). The effect of
genotype and treatment was analyzed using ANOVA, followed by
Bonferroni–Dunn post hoc tests.
On day 17, mice were sacriﬁced by cervical dislocation and rapid
decapitation. With reference to a mouse atlas (Paxinos and Franklin,
2001), the ventral striatum (~+1.00 to +0.80 mm AP from Bregma)
and ventromedial prefrontal cortex (~+1.90 to +1.70 mm AP from
Bregma) were dissected by micropunch on ice, ﬂash frozen in liquid
nitrogen and stored at−80 °C until analysis. Samples were sonicated in
Homogenization Buffer A (50 mM Tris–Cl, pH 7.5, containing 2 mM
dithiothreitol, 2 mM EDTA, 2 mM EGTA, 50 μM 4-(2-aminoethyl)-
benzenesulfonylﬂuoride hydrochloride, 50 mM KF, 50 nM okadaic
acid, 1 mM sodium orthovanidate, 5 mM sodium pyrophosphate, 0.1%
NP-40, and 5 μg/ml each of leupeptin, aprotinin, chymostatin, and
pepstatin A), spun in the Eppendorf 5810R centrifuge (Westbury, NY)
for 20 min at 4 °C at 20,000 rcf, and the clear homogenate was used as
total protein. Aliquots of crude whole-cell homogenates taken from the
frontal cortices of mice were used to determine the content of
phosphorylated and total protein. Protein concentrations were deter-
mined using the Bio-Rad (Hercules, CA) protein assay kit, and the
linearity of the protein concentration for immunoblotting was ascer-
tained by resolution of selected concentrations of protein. Equal
amounts of proteins were subjected to 10% SDS-PAGE gels and
separated by electrophoresis. β-actin was used as an internal control,
with no differences observed between genotypes. Proteins were then
electrophoretically transferred to nitrocellulose membranes. Nonspe-
ciﬁc binding on the nitrocellulose was blocked with Tris Buffered Saline
plus Tween 20 (TBST), 10% nonfat dry milk, and then incubated with
anti-phospho-GAP43 antibody (Upstate Laboratories, Syracuse, NY),
anti-GAP43 antibody (Upstate Laboratories, Syracuse, NY), anti-
MARCKS antibody (Calbiochem, Gibbstown, NJ), and anti-phospho-
MARCKS (Ser 152/156) antibody (Cell Signaling Technology, Danvers,
MA). The secondary antibodies were horseradish peroxidase-conjugat-
ed goat anti-rabbit IgG and goat anti-mouse IgG (Cell Signaling
Technology, Danvers, MA). The ECL plus kit (GE Healthcare, Piscataway,
NJ) was used as a detection system. Notably, in these experiments,
nitrocellulose membranes were ﬁrst probed with anti-phospho-
MARCKS, anti-phospho-GAP43 and then stripped with stripping buffer
and re-probed with the anti-MARCKS and anti-GAP43 antibodies.
Quantiﬁcation of the immunoblots was performed by densitometric
scanning of the X-ray ﬁlm using a Kodak Image Station 440 CF and
Kodak 1D ImageAnalysis Software (Eastman Kodak, Rochester, NY). For
each gel, the net and sum intensitywas determined by the software. Net
intensitywithin eachgelwasnormalized to the averaged gel-value from
control-treatedWT and the effect of genotype analyzed using Student's
t-test.Results
GluA1 KO exhibited locomotor hyperactivity in response to novelty and
mild stress
KO traveled signiﬁcantly farther than WT in a novel open ﬁeld
(t=9.16, df=27, pb .01) (Fig. 1A). By contrast, movement in a home-
cage-like environment was no different between genotypes (Fig. 1B).
KO traveled signiﬁcantly farther than WT before injection stress (main
effect of genotype: F1,13=123.92, pb .01). Injection stress produced a
transient (min 31 vs. min 30) decrease in locomotor activity in WT but
an increase in activity in KO (genotype× time interaction:
F28,364=6.03, pb .01) (Fig. 1C). A separate cohort of KO traveled
signiﬁcantly farther than WT before restraint stress (main effect of
genotype: F1,16=31.37, pb .01). Restraint stress produced a transient
(min 31 vs. min 30) increase in locomotor activity in both genotypes,
but a greater increase in KO than in WT (genotype×time interaction:
F29,464=3.41, pb .01) (Fig. 1D).GluA1 KO showed decreased immobility during forced swim
KO exhibited signiﬁcantly less immobility than WT over each of 2
FST trials, although the magnitude of the difference was greater on
trial 1 than trial 2 (genotype×trial interaction: F1,28=21.34, Pb .01)
and both genotypes showed a signiﬁcant increase in immobility
across trials (Fig. 2A). When a separate cohort was tested over 5×10-
min FST trials, KO displayed signiﬁcantly less immobility than WT
during trial 1 but not trials 2–5 (genotype×trial interaction:
F4,116=7.49, pb .01) (Fig. 2B). Post hoc tests revealed that KO, but
not WT, showed a signiﬁcant increase in immobility by trial 3, as
compared to trial 1. In a swim-naïve cohort, serum corticosterone was
similarly elevated inWT and KO after a single FST trial, relative to non-
stressed baseline (main effect of stress: F1,17=12.51, pb .01; main
effect of genotype: ns; stress×genotype interaction: ns) (Fig. 2C).GluA1 KO showed increased swimming in a modiﬁed forced swim test
KO showed signiﬁcantly less immobility (genotype×trial interaction:
F1,46=18.98, pb .01) andmore swimming (genotype×trial interaction:
F1,46=21.54, pb .01), but no difference in climbing (all effects: ns),
relative to WT, on trial 1 (Figs. 3A,B) but not trial 2 (Figs. 3C,D). KO, but
not WT, showed a signiﬁcant increase in immobility and a decrease in
swimming from trial 1 to 2.GluA1 KO showed increased open arm/quadrant exploration in elevated
maze tests
In the elevated plus-maze (NIAAA), KO made signiﬁcantly more
open (t=3.10, df=25, pb .01) and center (t=2.53, df=25, pb .05),
but not closed, entries than WT (Fig. 4A). KO also had signiﬁcantly
more center (t=3.62, df=25, pb .01) time and a trend for more open
time (t=1.97, df=25, p=.0605), but less closed time (t=6.56,
df=25, pb .01) than WT (Fig. 4B).
In the elevated plus-maze (Oxford), KO made signiﬁcantly more
open (t=3.41, df=90, pb .01) and center (t=4.63, df=90, pb .01),
but not closed, entries than WT (Fig. 4C). KO also had signiﬁcantly
more center (t=2.78, df=90, pb .01) time and a trend for more open
time (t=1.90, df=90, p=.0608), but less closed time (t=10.06,
df=90, pb .01) than WT (Fig. 4D).
In the elevated zero-maze (Mannheim), KO made signiﬁcantly
fewer open entries (t=3.36, df=13, pb .01) (Fig. 4E) and showed a
non-signiﬁcant trend for less open quadrant time (t=2.10, df=13,
p=.0554) than WT (Fig. 4F).
Fig. 1. GluA1 KO exhibited locomotor hyperactivity in response to novelty and mild stress. (A) KO traveled signiﬁcantly farther than WT in a 10 min exposure to a novel open ﬁeld
(**pb .01) (n=15/genotype). (B) Movement in a home-cage-like environment was not different between genotypes (n=45–47/genotype). (C) KO traveled signiﬁcantly farther
than WT before injection stress. Injection stress produced a transient decrease in locomotor activity in WT but an increase in activity in KO (*pb .05 vs. minute 31 in WT; #pb .05 vs.
minute 30 in same genotype) (n=7–8/genotype). (D) KO traveled signiﬁcantly farther than WT before restraint stress. Restraint stress produced a transient increase in locomotor
activity in both genotypes, but a greater increase in KO (n=9–10/genotype). Data are Means±SEM.
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hyperthermia
In the light/dark emergence test, KO made signiﬁcantly more
shelter exits (t=2.15, df=26, pb .05) and showed more frequent
scanning from the shelter (t=2.20, df=26, pb .05) thanWT (Fig. 5A).
KO did not spend signiﬁcantly more time out of the shelter than WT,
but engaged inmore time scanning thanWT (t=2.34, df=26, pb .05)
(Fig. 5B).
KO showed a near signiﬁcant trend for greater stress-induced
hyperthermia than WT (t=2.12, df=11, p=.0580) (Fig. 5C). Basal
temperature was signiﬁcantly higher inWT than KO (WT=36.7±.42,
KO=35.7±.19; t=2.32, df=11, pb .05).
In a naïve cohort tested over 2 exposures to the elevated plus-
maze (NIAAA), KO made signiﬁcantly more open entries than WT,
regardless of trial (main effect of genotype: F1,38=24.79, pb .01,
main effect of trial: ns, genotype×trial interaction: ns) (Fig. 5D). KO
also showed signiﬁcantly more open time than WT regardless of trial
(main effect of genotype: F1,38=11.24, pb .01;main effect of trial: ns;
genotype×trial interaction: ns) (WT/trial 1 (sec)=15.0±2.4, KO/
trial 1=26.1±3.7, WT/trial 2=12.2±3.1, KO/trial 2=30.0±4.7).
Closed arm entries were not different between genotypes on trial 1,
but were greater in KO than WT on trial 2 (genotype×trial interaction:
F1,38=4.94, pb .05; WT/trial 1=15.3±1.2, KO/trial 1=15.4±1.5,
WT/trial 2=14.3±1.5, KO/trial 2=20.0±2.3).
GYKI 52466 did not mimic GluA1 locomotor phenotype in C57BL/6J,
or alter GluA1 KO phenotype
GYKI 52466 treatmentdidnot signiﬁcantly alter openﬁeld locomotor
activity or elevated plus-maze behavior, relative to vehicle, in non-
mutant C57BL/6J mice (Table 2). Note, although GYKI 52466 and other
AMPAR antagonists produce anxiolytic-like effects in rats (Alt et al.,
2006; da Cunha et al., 2008; Kapus et al., 2008; Kotlinska and Liljequist,
1998;Matheus andGuimaraes, 1997; Turski et al., 1992), previous work
inNMRImice (light/dark emergence test) (Kapus et al., 2008) andTurku
Aggressive mice (social interaction test) (Vekovischeva et al., 2007)
found negative (as here) or anxiogenic-like effects in that species.In KO, GYKI 52466 treatment did not alter the open ﬁeld locomotor
hyperactivity phenotype (main effect of genotype: F1,15=35.33, pb .01;
main effect of drug: ns; genotype×drug interaction: ns) (Table 2).
Psychostimulants exacerbated GluA1 KO locomotor phenotype
Treatment with amphetamine increased total distance traveled
relative to pre-drug baseline in both WT and KO (drug×genotype
interaction: F1,17=5.27, pb .05; WT drug vs. baseline Bonferroni
correct t-test: t=3.24, df=9, pb .05; KO drug vs. baseline Bonferroni
correct t-test: t=4.17, df=8, pb .01) (Fig. 6A). However, there was a
signiﬁcantly greater drug-induced increase (relative to pre-drug
baseline) in KO than WT (t=2.32, df=16, pb .05) (Fig. 6A, inset).
Total distance traveled was greater in KO thanWT after amphetamine
treatment, but not during pre-drug baseline activity (likely because
this baseline comprised the last 10 min of a 60-min acclimation
period, with no injection).
In a separate cohort, treatment with methylphenidate increased
total distance traveled relative to vehicle in both WT and KO, and KO
traveled farther than WT regardless of treatment (main effect of
genotype: F1,32=157.57, pb .01; main effect of drug: F1,32=30.96,
pb .01; genotype×drug interaction: ns) (Fig. 6B). However, despite
the absence of a genotype×drug interaction, methylphenidate
produced a signiﬁcantly greater increase in locomotor activity in KO
than WT when measured as the increase from vehicle (t=2.30,
df=17, pb .05) (Fig. 6B, inset).
Rapid dopamine depletion paradoxically exacerbated GluA1 KO
locomotor phenotype
Vehicle treated KO traveled signiﬁcantly farther than WT, and
AMPT treatment produced an additional signiﬁcant increase in
KO, but had no effect in WT (genotype×treatment interaction:
F2,51=7.90, pb .01) (Table 3). Post mortem striatal tissue levels
of monoamines and their metabolites did not differ between
genotypes at baseline (all main effects of genotype: ns). AMPT
treatment signiﬁcantly decreased striatal dopamine (main effect of
treatment: F1,37=24.49, pb .01), DOPAC (main effect of treatment:
Fig. 2. GluA1 KO showed decreased immobility in the forced swim test. (A) KO exhibited
signiﬁcantly less immobility than WT over each of 2 FST trials, although the effect was
larger duringmin 3–6 of a 15-min trial 1 thanmin 3–6 of a 6-min trial 2 (**pb .01, vs. WT/
same trial). WT and KO both showed increased immobility from trial 1 to 2 (##pb .01 vs.
trial 1/same genotype) (n=15/genotype). (B) When tested over 5×10 min FST trials,
KO displayed less immobility than WT during trial 1 (*pb .05) but not trials 2–5. KO
showed a signiﬁcant increase in immobility by trial 3 (#pb .05) (n=13–18/genotype).
(C) Serum corticosterone was similarly elevated in WT and KO after a single FST trial,
relative to non-stressed baseline (†pb .05 vs. base) (n=4–6/genotype/stress condition).
Data are Means±SEM.
Fig. 3. GluA1 KO showed increased swimming in a modiﬁed forced swim test. (A) KO
showed signiﬁcantly less immobility and more swimming on trial 1 (**pb .01 vs. WT).
(B) Climbing did not differ between genotypes on trial 1. (C) KO showed an increase in
immobility and a decrease in swimmingon trial 2, relative to trial 1, and did not differ from
WT in either behavior on this trial (##pb .01 vs. trial 1/KO). (D) Climbing did not differ
between genotypes on trial 2. n=22–26/genotype. Data are Means±SEM.
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pb .01), and 3-MT (main effect of treatment: F1,37=20.50, pb .01),
irrespective of genotype (Table 3). Norepinephrine content was
unaffected by treatment or genotype. AMPT treatment signiﬁcantly
increased striatal tissue levels of 5-HT regardless of genotype (main
effect of treatment: F1,37=9.27, pb .01), but increased 5-HIAA only in
KO (genotype×treatment interaction: F1,37=7.29, pb .05) (Table 3).
GSK-3β inhibitor did not rescue GluA1 KO locomotor phenotype
KO traveled signiﬁcantly farther than WT, regardless of treatment,
although therewas a borderline genotype×treatment interaction (main
effect of genotype: F1,47=33.37, pb .01; main effect of treatment: ns;
genotype×treatment interaction: F1,47=3.55, p=.0657) due to a
trend for SB216763 treatment to reduce locomotor hyperactivity in KO
(Table 4). KO showed signiﬁcantly less immobility thanWT across 2 FST
trials, regardless of SB216763 treatment (main effect of genotype:
F1,48=21.65, pb .01: main effect and interactions with treatment: ns)(Table4). Immobility increased fromtrial 1 to2 regardless of genotypeor
treatment (main effect of trial: F1,48=27.58, pb .01).
Lithium partially rescued GluA1 KO phenotype
In the elevated plus-maze, KO receiving control treatment, but not
lithium treatment, made signiﬁcantly more open entries than WT
(genotype×treatment interaction: F1,30=5.12, pb .05) (Fig. 7A) and
showed a near signiﬁcant trend for more percent open time than WT
(WT/control=17.0±3.0, WT/lithium=14.8±3.7, KO/control=48.3
±5.5, KO/lithium=22.0±11.1; genotype×treatment interaction:
F1,30=4.06, p=.053). Two lithium-treatedKO thatmadeno armentries
were excluded from the plus-maze analysis. Closed arm entries were
unaffected by genotype or treatment (data not shown).
In the novel open ﬁeld (Fig. 7B), there was a signiﬁcant main effect of
genotype (F1,56=151.83, pb .01), as well as a signiﬁcant interaction
between genotype and 2-min timebin (F4,224=18.72, pb .01) and
treatmentand timebin(F4,224=11.07,pb .01) for total distance traveled.
Post hoc tests showed thatwhereas control dietKOweremoreactive than
control dietWT for all timebins, lithiumtreatment reducedactivityduring
the ﬁrst 2-min timebin in both genotypes such that activity in lithium-
treated KO was normalized to WT control levels. Lithium treatment also
reducedactivity inKO, relative to control-treatedKO,during the second2-
min timebin but was ineffective in timebins thereafter. In the fourth and
ﬁfth timebins, lithium treatment increased activity in WT. One lithium-
treated WT had a seizure at the start of the test, and was excluded from
open ﬁeld analysis. Three other mice (1 control chow-treated KO, 2
lithium-treated WT) were greater or less than 2 standard deviation
outliers for total distance traveled for their treatment group, and were
excluded from this analysis. Plasma lithium levels measured after the
open ﬁeld were in the therapeutic range inWT (1.05±0.07 mEq/L) and
KO (1.15±0.14 mEq/L). Lithium treatment signiﬁcantly reduced body
weight relative to control treatment (lithiumWTweight change relative
to pre-drug: −11.8±1.6%; control WT change: +1.8±0.9%; lithium
KO: −10.9±2.5%; control KO: +1.9±1.2%) (main effect of treatment:
F1,56=64.98, pb .01; main effect of genotype: ns).
Fig. 4. GluA1 KO showed increased open arm/quadrant entries and increased center time in elevated maze tests. (A) In the NIAAA elevated plus-maze, KO made more open and
center, but not closed, entries thanWT (*pb .05 vs. WT) (n=14–15/genotype). (B) KO showed more center time and less closed time, and a trend for more open time, as compared
to WT (**pb .01 vs. WT). (C) In the Oxford elevated plus-maze, KO made more open and center, but not closed, entries than WT (**pb .01 vs. WT) (n=45–47/genotype). (D) KO
showed more center time and less closed time, and a trend for more open time, as compared to WT (**pb .01 vs. WT). (E) In the elevated zero-maze (Mannheim), KO made fewer
open entries (**pb .01) and (F) showed a non-signiﬁcant trend for less open quadrant time than WT (n=7–8/genotype). Data are Means±SEM.
Fig. 5. GluA1 KO showed increased exits and risk assessment in the light/dark emergence test and a trend for greater stress-induced hyperthermia. (A) In the light/dark emergence
test, KO made more shelter exits and showed more frequent scanning than WT (*pb .05 vs. WT) (n=15/genotype). (B) KO did not spend signiﬁcantly more time out of the shelter
than WT, but engaged in more time scanning from the shelter than WT (*pb .05 vs. WT). (C) KO showed a trend for greater stress-induced hyperthermia than WT (n=6–7/
genotype). (D) In the elevated plus-maze, KO made signiﬁcantly more open entries than WT, regardless of trial (n=18–22/genotype). Data are Means±SEM.
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Table 2
Effects of AMPA/kainate antagonist GYKI 52466 in non-mutant C57BL/6J and GluA1 KO. GYKI 52466 did not affect novel open ﬁeld locomotor activity or elevated plus-maze anxiety-
related behavior (n=8–9/dose) in C57BL/6J. GYKI 52466 did not alter the GluA1 KO open ﬁeld locomotor hyperactivity phenotype (n=6–11/genotype). Data are means±SEM.
C57BL/6J
GYKI 52466 dose (mg/kg)
0 0.5 2.5 5 10
Novel open ﬁeld locomotor activity
Total distance traveled (m) 41.9±2.0 44.5±3.7 49.0±2.3 47.6±3.3 40.3±2.6
Elevated plus-maze anxiety-related behavior
Open arm entries 5.6±1.0 5.1±1.4 6.1±1.1 6.4±0.7 7.6±1.4
Closed arm entries 22.3±1.5 21.4±1.6 19.9±1.5 20.3±1.3 24.6±1.5
%Time in open arms 7.4±1.8 6.4±2.4 9.7±2.7 9.8±2.2 13.6±3.5
%Time in closed arms 58.2±1.6 56.3±1.8 59.5±3.1 59.2±2.7 61.6±2.9
GluA1 KO
Locomotor hyperactivity
WT/VEH WT/GYKI KO/VEH KO/GYKI
Total distance traveled (m) 87.7±6.8 81.6±8.6 168.5±12.3 157.2±18.2
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cantly higher in control-treated (t=3.49, df=10, pb .01) but not lithium-
treated KO relative to WT (Fig. 7C). Levels of phospho-neuromodulin in
PFC were also signiﬁcantly higher in control-treated (t=3.19, df=10,
pb .01) but not lithium-treatedKO relative toWT (Fig. 7D). Genotypes did
not differ in striatal phospho-MARCKS (WT/control=1.0±0.1, WT/




The goal of the current study was to test whether mutant mice
lacking GluA1 AMPAR subunit exhibit ‘mania-related’ phenotypic
abnormalities. Taken together with earlier studies demonstrating thatFig. 6. Psychostimulants exacerbated GluA1 locomotor phenotype. (A) Amphetamine produc
##pb .01 vs. baseline). KO given amphetamine traveled signiﬁcantly farther thanWT given th
activity in KO than WT (inset) (*pb .05) (n=9/genotype). (B) Methylphenidate signiﬁcant
signiﬁcantly greater in KO than WT (inset) (*pb .05) (n=9/genotype/treatment). Data areGluA1 KO exhibit schizophrenia- and depression-related phenotypes
under certain conditions, the current study suggests that these mice
phenocopy features of schizoaffective disorder.
Replicating a phenotype consistently observed in our laboratories
and elsewhere (Bannerman et al., 2004; Chourbaji et al., 2008;
Vekovischeva et al., 2004; Wiedholz et al., 2008), GluA1 KO showed a
marked hyperlocomotor response during exposure to a novel open
ﬁeld. Importantly, this is a speciﬁc response to novelty rather than
chronic elevation of locomotor activity, because here and previously
(Wiedholz et al., 2008), we have shown that GluA1 KO display normal
locomotion in the familiar environment of the home cage. Thus, KO
appear to be highly sensitive to the stimulatory/provocative char-
acteristics of a novel environment and, indeed, are slow to habituate
to such environments (Sanderson et al., 2009). Extending these
ﬁndings, current data show that open ﬁeld locomotor hyperactivityed a signiﬁcant increase in open ﬁeld total distance traveled in both genotypes (#pb .05,
is drug (**pb .01). There was a signiﬁcantly greater drug-induced increase in locomotor
ly increased total distance traveled in both genotypes. The drug-induced increase was
Means±SEM.
Table 3
Rapid dopamine depletion by AMPT paradoxically exacerbated GluA1 locomotor hyperactivity. Vehicle treated KO traveled signiﬁcantly farther than WT, whereas AMPT treatment
produced a further increase in KO but had no effect inWT (&&pb .01 vs. WT/same treatment; #pb .05 vs. KO/vehicle) (n=12–16/genotype/treatment). AMPT treatment decreased
striatal tissue levels (ng/g tissue) of dopamine, DOPAC, HVA, and 3-MT, irrespective of genotype (n=10–11/genotype/treatment) (**pb0.01). AMPT treatment signiﬁcantly
increased striatal serotonin regardless of genotype (††pb0.01), but increased 5-HIAA only in KO (#pb .05 vs. KO/vehicle). Norepinephrine content was unaffected by treatment or
genotype. Data are Means±SEM.
WT KO
VEH AMPT VEH AMPT
Novel open ﬁeld
Total distance traveled (m) 61.6±5.9 49.2±4.2 115.2±11.7&& 155.9±15.4&&#
Striatal monoamine levels
Dopamine** 3555.8±599.1 937.5±281.9 2797.6±461.5 1235.1±285.8
DOPAC** 344.7±32.9 80.8±15.3 270.8±33.9 84.8±10.1
HVA** 649.6±76.6 196.2±26.4 561.4±79.4 241.3±34.3
3-MT** 123.8±17.1 31.9±10.7 93.2±18.1 50.2±13.2
Serotonin†† 1080.6±46.9 1202.3±65.3 1054.7±64.9 1343.2±86.4
5-HIAA 657.8±49.2 557.7±48.3 540.8±41.5 720.8±65.9#
Norepinephrine 565.6±55.0 569.5±55.2 685.4±58.6 578.9±48.6
618 P.J. Fitzgerald et al. / Neurobiology of Disease 40 (2010) 608–621can also be provoked in GluA1 KO by exposure to even mild stress.
Following a single intraperitoneal saline injection, locomotor activity
was suppressed in WT but transiently increased above already
elevated baseline levels in GluA1 KO. Similarly, after 5-min restraint,
GluA1 KO again showed an exaggerated short-lasting increase in open
ﬁeld locomotor activity. Collectively, these data show that KO are
highly sensitive to environmental provocation, and behaviorally
express this response in an open ﬁeld setting with hyperactivity.
GluA1 KO also showed a strong locomotor activity response
(reduced immobility) to the more intense stress of forced swim. As
with the openﬁeld locomotorhyperactivity phenotype, the forced swim
phenotype was highly consistent across different cohorts of mice and
across laboratories. Of note, the response diminished with repeated
exposure, providing another indication that the hyperactivity response
in these mice is particularly strong to novel stimuli. Moreover, a
modiﬁed version of the test revealed that the reduced immobility was
the result of increased swimming behavior but not climbing. Given that
reductions in immobility due to increased swimming are produced by
antidepressant treatments that boost serotonin, rather than catechol-
amine, levels (Cryanet al., 2005), this phenotype couldbe interpreted as
a serotonin-related antidepressant-like response (note, basal hippo-
campal serotonin levels are depressed in GluA1 KO; Chourbaji et al.,
2008). However, given our open ﬁeld data in KO, together with clinical
data showing that stress exacerbates psychomotor symptoms in bipolar
disorder and schizophrenia (Ambelas, 1979; Malkoff-Schwartz et al.,
2000), a more parsimonious interpretation is that the forced swim
behavior of these mice is a manifestation of a ‘manic-like’ hyperloco-
motor response. Previous studies have similarly interpreted this
combination of behavioral abnormalities in other KOs (e.g., Clock KO:
Roybal et al., 2007; GluA6 KO: Shaltiel et al., 2008).Table 4
GSK-3β inhibitor did not rescue GluA1 locomotor phenotype. KO traveled signiﬁcantly
farther than WT, regardless of treatment, although there was a trend for SB216763
treatment to reduce locomotor hyperactivity in KO (n=13/genotype/treatment). KO
showed signiﬁcantly less immobility than WT across 2 FST trials, regardless of
SB216763 treatment. Immobility (min 3–6) increased from trial 1 to 2 regardless of
genotype or treatment. (n=13/genotype/treatment; samemice as for novel open ﬁeld
test). Data are Means±SEM.
WT KO
VEH SB216763 VEH SB216763
Novel open ﬁeld
Total distance traveled (m) 36.4±4.7 34.8±6.1 71.7±9.1 55.6±3.4
Forced swim test
Trial 1 percent immobility 34.1±7.0 39.4±6.4 12.7±3.0 12.5±3.5
Trial 2 percent immobility 49.7±7.5 62.7±6.9 30.6±7.6 35.1±7.2Schizophrenia and bipolar disorder are often comorbid with anxiety
disorders, althoughbipolar disorder ismore likely to be characterizedby
risk-taking and novelty-seeking (DSM-IV, 1994). GluA1 KO showed
increased entries into the open armsof the elevated plus-maze and light
compartment of the light/dark emergence test, as well as consistent
trends for increased time spent in these areas. This was another
phenotype that was remarkably stable across different laboratories and
genetic backgrounds (C57BL/6J and C57BL/6JxCBA/J hybrid), which is
particularly notable given evidence that the penetrance of mutant
phenotypes in the elevated plus-maze can varywith laboratory (Crabbe
et al., 1999) and background (Holmes and Hariri, 2003). Our data are
also in general agreement with earlier work showing increased light-
compartment exploration and trends for increased open arm time
(Vekovischeva et al., 2004). Such proﬁles are typically interpreted as a
decrease in anxiety-like behavior.
However, these anxiety tests are based upon a conﬂict between
threat-related avoidance and novelty-driven approach (Cryan and
Holmes, 2005). In this context, data from other tests and previous
studies do not ﬁt well with a decrease in anxiety-like behavior in GluA1
KO and instead indicate a more complex phenotype. KO exhibited a
proﬁle in the elevated zero-maze and stress-induced hyperthermia
assays more consistent with heightened anxiety-like behavior. It is
conceivable that the greater increase in core body temperature in KO
could reﬂect increased muscle activity resulting from stress-induced
motor hyperactivity. Nevertheless, the proﬁle in the zero-maze
resembles earlier data in the hyponeophagia and black/white alley
tests (Bannerman et al., 2004). In addition, KO showed a strong
preference for the center of the elevatedplus-maze and spentmore time
scanning the light compartment, behaviors reﬂective of risk assessment
(Blanchard and Blanchard, 1989; Holmes and Rodgers, 1998). Thus,
taken collectively and with our ﬁndings in other tests, the proﬁle in the
plus-maze may reﬂect a manic-like increase in approach behavior
perhaps related to heightened ‘novelty-seeking’ or ‘risk-taking.’ Clearly
though, additional experiments will be needed to fully understand the
nature of this phenotype. For example, it is not clear which facet of
certain tests (plus-maze, light/dark) brings out the KO approach
behavior that is not present in others (zero-maze, black/white alley,
hyponeophagia) where KO actually show less approach. Of course the
distribution of time spent in the different sections of thesemazeswill, in
part, reﬂect the relative ability of each section to induce exploration
which in turn will depend on the salience of the different sections, the
starting location of the mouse, and the rate of habituation in the
different genotypes (Sanderson et al., 2009), resulting in a complex set
of interactions that could differ from one test to the next. Indeed, these
data underscore the complexity of these ostensibly simple mouse
behavioral tasks that are commonly employed, but not always carefully
interpreted (Holmes, 2001).
Fig. 7. Lithium partially rescued GluA1 locomotor and PKC phenotype. (A) In the elevated plus-maze, KO receiving control treatment, but not lithium treatment, made signiﬁcantly
more open entries than WT (n=7–9/genotype/treatment) (**pb .01 vs. WT/control; #pb .05 vs. KO/control). (B) In the novel open ﬁeld, control KO were more active than control
WT for all 2-min timebins, and lithium treatment reduced activity during the ﬁrst timebin in both genotypes such that activity in lithium-treated KO was normalized to WT control
levels. Lithium treatment also reduced activity in KO, relative to control-treated KO, during the second timebin but was ineffective in timebins thereafter. In the fourth and ﬁfth
timebins, lithium treatment increased activity in WT. (*pb .01 KO/control vs. WT/control, #pb .05 lithium vs. control/same genotype) (n=14–17/genotype/treatment). (C) Levels
of phospho-MARCKS in PFC were signiﬁcantly higher in control-treated but not lithium-treated KO relative to WT (n=5–6/genotype/treatment). (D) Levels of phospho-
neuromodulin in PFC were also signiﬁcantly higher in control-treated but not lithium-treated KO relative to WT (n=6/genotype/treatment). (**pb .01 vs. WT/control; ##pb .01,
#pb .05 vs. KO/control). Data are Means±SEM.
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approach, at least in certain tests, displayed by GluA1 KO models
positive symptoms in schizophrenia and the manic-like component of
schizoaffective disorder, it also resembles other neuropsychiatric
disorders, including Attention Deﬁcit Hyperactivity Disorder (ADHD)
(Brigman et al., 2010; Gainetdinov et al., 1999; Powell and Miyakawa,
2006). For example, dopamine transporter (DAT) KO also exhibit
novelty-induced locomotor hyperactivity, and this phenotype is
normalized by psychostimulants that produce paradoxical calming
effects in persons with ADHD (Gainetdinov et al., 1999). A model of
bipolar mania or schizophrenia, by contrast, would be expected to be
worsened not rescued by psychostimulants, in line with the response
shown by schizophrenics and manic persons. Consistent with this, and
arguing against an ADHD-like phenotype, acute treatment with the
psychostimulant anti-ADHD drugs, amphetamine (Adderall) and
methylphenidate (Ritalin), exacerbated rather than reversed open
ﬁeld hyperactivity in KO. One caveat here is that these effects were
observed over a relatively short, 10-min, test session, precluding a fuller
examination of the time course of genotype differences in psychosti-
mulant responsivity.
Another set of important pharmacological ﬁndings was that two
weeks of treatment with the anti-manic drug, lithium, normalized the
GluA1 phenotype in the elevated plus-maze, although only partially in
the novel open ﬁeld. A similar lithium treatment regimen normalized
mania-related behavior in the elevated plus-maze, but not novel open
ﬁeld, in Clock mutant mice (Roybal et al., 2007) (but not GluA6 KO,
Shaltiel et al., 2008). The relative insensitivity of the open ﬁeld
hyperactivity in GluA1 and Clockmutants to lithium treatmentmay be
a reﬂection of the relatively greater strength of this phenotype. The
GSK-3β inhibitor, SB216763, had weak but non-signiﬁcant reversing
effects on the open ﬁeld but not forced swim hyperactivity phenotype
of GluA1 KO. The GSK-3β pathway is a major target of lithium (Gould
and Manji, 2005) and SB216763 was recently shown to normalize
open ﬁeld and forced swim hyperactivity in DISC1 mutant mice (Maoet al., 2009). Additional studies are warranted to further probe the
GSK-3β pathway in GluA1 KO. However, taken together, the main
conclusion from these experiments is that anti-manic drugs rescue at
least a subset of the behavioral abnormalities in GluA1 KO. This
extends our previous ﬁnding that haloperidol, an antipsychotic with
efﬁcacy in schizophrenia and mania, also normalizes behavior (in that
instance, hyperlocomotion) in GluA1 KO (Wiedholz et al., 2008). This
pattern of pharmacological rescue further speaks to a KO phenotype
that may have features relevant to both mania and schizophrenia.
In this context, the ability of lithium to rescue phenotypic
abnormalities in GluA1 KO was paralleled by normalization of elevated
phosphorylation ofMARCKS andneuromodulin, twomarkers of the PKC
pathway that interact with GluA1 and are implicated in mania (Szabo
et al., 2009). Thesemolecular abnormalities and their reversal by lithium
were seen in PFCbutnot striatum, suggesting theprimary PKCalteration
was at the cortical level. This raises the possibility that the increased
plus-maze approach phenotype in KO is driven by PFC dysfunction
(although note that excitotoxic PFC lesions do not typically affect this
behavior: Holmes andWellman, 2009; Rudebeck et al., 2007), while the
novelty-induced hyperactivity phenotype may occur independently of
frontal regions. It has been suggested that the openﬁeld hyperactivity in
thesemicehas a striatal and dopaminergic basis because of our previous
ﬁnding of reduced striatal dopamine clearance and aforementioned
phenotypic rescue by haloperidol (a dopamine D2 receptor antagonist)
(Wiedholz et al., 2008). On the other hand, a surprisingﬁnding from the
current studywas that rapid depletion of dopamine via AMPT treatment
did not reverse open ﬁeld hyperactivity in GluA1 KO (as it does in DAT
KO: Costa et al., 2006; Gainetdinov et al., 1999), but actually exacerbated
the phenotype despite effectively depleting striatal dopamine tissue
levels. The reasons for this paradoxical response are unclear and require
further study.
The study of constitutive GluA1 KO does not allow us to distinguish
between effects of GluA1 absence just during adulthood and conse-
quences arising fromdevelopmental disturbances. Of note in this context,
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pal expression of calcium signaling proteins in GluA1 KO (Zhou et al.,
2009). Although we found that non-mutant C57BL/6J mice systemically
treated with the subunit-non-selective competitive AMPAR antagonist,
GYKI52466,didnot showKO-likehyperactivityor approachbehavior this
cannot be readily equated with the complete, subunit-speciﬁc nature of
the GluA1 KO. Notwithstanding, we cannot exclude the possibility that
the mania-related phenotype in GluA1 KO is the consequence of a
complex set of changes in glutamate neurotransmission as well as
ontogenic insults in, for example, corticostriatal wiring. This would not,
however, lessen the potential validity of the mutant as a model of a
human affective or psychotic disorder, which are themselves posited to
have a major developmental etiological component (Hariri and Holmes,
2006; Harrison andWeinberger, 2005). Another potential issue that was
not fully addressed in the current study is the possible modifying
inﬂuence of sex on the GluA1 phenotype. We had previously found no
evidence that male and female GluA1 KO differed on various phenotypic
measures, including schizophrenia- and fear-related behaviors (Feyder
et al., 2007;Wiedholz et al., 2008) and therefore did not design or power
the current study to address sex as an interacting factor. We therefore
cannotwholly discount a possible sex inﬂuence on the currentmeasures,
and this remains another interesting question for future studies in these
mutants.
In summary, the current study demonstrates that KO of GluA1
produces a profound and selective increase in locomotor activity in
response to novelty, andmild and intense stressors. GluA1KOdisplayed
a complex proﬁle in tests for anxiety-like behavior, with an increased
(novelty-seeking or risk-taking related) approach drive in some, but not
all, tests. At least some of these behavioral abnormalities were
normalized by the anti-manic drug lithium, butwere aggravated further
by psychostimulants and by rapid dopamine depletion. GluA1 KO and
increased approach behaviors were associated with increased PKC
activity in PFC. Taken together with previous studies showing these
mice exhibit schizophrenia- and depression-related abnormalities, we
propose that these mice may phenocopy features of schizoaffective
disorder and provide a novel tool for studying the pathophysiology of
this disorder.
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